fashion -WSS

fashion

author：knowledge 2025-09-27 17:11:34 - browse：79757

Dozens of sickle cells in a whirlpool — coverage from STAT — Adobe

Nearly a decade ago, consultants delivered to Rodger Novak a kind of Sears catalog of human malady: 200 pages, listing dozens of different diseases, each annotated with — from a business standpoint — their best and worst attributes.

The document was supposed to help Novak, then the chief executive of CRISPR Therapeutics, navigate a pressing quandary. His company, along with two others, were founded to commercialize the new revolutionary gene-editing tool CRISPR-Cas9, which promised to cure numerous genetic diseases. But which should they target first? What was the best proof-of-concept?

“We looked at anything and everything,” said Novak, who stepped down as CEO in 2017 but remained on the board until this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Telehealth for opioid use disorder is lifesaving

WSS

Private equity could exacerbate cardiology's overuse problem, experts fear

TB outbreak tied to bone grafts underscores testing shortcomings

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

After John Oliver segment, STAT readers share their opioid

Food makers to regulators: Ultra

Telehealth for opioid use disorder is lifesaving

focus

fashion

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Novo acquires Inversago for up to $1 billion

Anesthesiologist group: stop taking Ozempic before surgery

WATCH: Why do bright lights make us see spots?

Medicare proposal to cover medical devices draws a mixed reaction

WATCH: Why do bright lights make us see spots?

Cancer drug shortages should be causing more outrage

FDA panel endorses Alnylam’s heart drug — after picking it apart

How one medical school became remarkably diverse

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

hotspot

Diverse clinical trials: Why aren’t we there yet?

FDA panel endorses Alnylam’s heart drug — after picking it apart

Generate Biomedicines machine learning biotech raises $273M

The history of OxyContin, told through Purdue Pharma documents

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

focus

hotspot

hotspot

entertainment